About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors

By: via Business Wire

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John F. Thero to its board of directors. Mr. Thero will chair the audit committee. His appointment will increase the number of Cyteir board directors from eight to nine.

Mr. Thero is an accomplished financial and operations executive with more than 30 years of experience in senior roles, including more than 20 years supporting the growth of life science companies. In 2019, Mr. Thero was named Ernst & Young LLP Entrepreneur of the Year for Life Sciences.

“John has valuable experience in helping emerging growth companies overcome challenges and create shareholder value. He has successfully developed and launched new products, most notably Amarin’s VASCEPA®, and entered various forms of strategic relationships with larger companies. As Cyteir grows, John’s insights and experience will be very helpful to Cyteir,” said Markus Renschler, MD, President and Chief Executive Officer of Cyteir. “On behalf of our entire board, we are excited to welcome John and look forward to his contributions.”

From 2009, until he elected to retire in August 2021, Mr. Thero was an executive officer at Amarin Corporation PLC, including serving as President since 2010 and as Chief Executive Officer and a member of its board of directors since 2014. During his tenure at Amarin, he helped successfully lead the company through clinical development, global regulatory approvals, and commercialization of VASCEPA®. Prior to Amarin, Mr. Thero served as Chief Financial Officer (CFO) at ViaCell, Inc., where he helped guide the company in its sale to PerkinElmer, and Abiomed, Inc., where he held multiple positions, including Senior Vice President of Business Operations and CFO. Mr. Thero began his professional career at Arthur Andersen LLP. He received a B.A. in Economics and Accounting from The College of the Holy Cross in Worcester, Massachusetts. He is currently a member of the board of directors at CinCor Pharma, Inc.

“I am excited to be joining the board of Cyteir Therapeutics as CYT-0851 advances and has the potential to become an important therapeutic option for oncology patients,” said Mr. Thero. “I look forward to working with the other members of the board and Cyteir’s management team to help drive growth and execution at Cyteir.”

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

Forward-Looking Statements

This press release contains “forward-looking statements” regarding Cyteir’s growth, strategy and anticipated clinical developments. Forward-looking statements include statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: our limited operating history; that we have incurred significant losses since inception and expect to incur losses for the foreseeable future and may never achieve or maintain profitability; our need for substantial additional funding; that we have never successfully completed any clinical trials; that our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our drug candidates; our intention to develop CYT-0851, and potentially future drug candidates, for use in combination with other therapies, which exposes us to additional risks; our ability to successfully develop and commercialize companion diagnostic tests for our drug candidates; negative perceptions of the efficacy, safety or tolerability of precision medicine targets; our ability to adequately protect and enforce our intellectual property or obtain and maintain patent protection for our technology and products appropriately scoped for our commercialization plans; the continuing outbreak of COVID-19 in the United States and other countries; and other factors described in our filings with the U.S. Securities and Exchange Commission (SEC) available on the SEC’s website at www.sec.gov, including under the heading “Risk Factors” in Cyteir’s final prospectus dated June 17, 2021 related to our initial public offering. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The company does not undertake any obligation to update any such statement or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Contacts

More News

View More
Is Tilray's Stock Price Surge a Pipe Dream of Political Hype?
Via MarketBeat
Topics Cannabis
Tickers TLRY
PayPal Stock: Why Wall Street May Be Undervaluing This Giant
Via MarketBeat
Topics Economy
Tickers PYPL
Why Vertical Aerospace Could Lead the eVTOL Market by 2028
Via MarketBeat
Tickers EVTL VTOL
Is Draganfly's Army Partnership a Game-Changer for Investors?
Via MarketBeat
Tickers DPRO
3 Auto Stocks to Watch as EV and Hybrid Demand Shifts
Via MarketBeat
Topics Economy Stocks World Trade
Tickers F GM TSLA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.